Skip to content

A clinical study on pre-AD

Construction and evaluation of a clinical prediction model for conversion of subjective cognitive decline into mild cognitive impairment

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058889
Enrollment
Unknown
Registered
2022-04-18
Start date
2022-04-09
Completion date
Unknown
Last updated
2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjective cognitive decline,Mild cognitive impairment,Alzheimer's disease

Interventions

Sponsors

The Second Affiliated Hospital of Bengbu Medical College
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Age between 45-75 years old; 2.SCD complies with the 2018 "Expert Consensus on Diagnosis Process and Specification of Preclinical Subjective Cognitive Decline in Alzheimer's Disease in China", that is, subjective sensory memory decline rather than other cognitive impairment, and there is concern about cognitive decline. 3.MCI meets the diagnostic criteria for MCI promulgated by the American Academy of Neurology in 2018, and does not meet the diagnostic criteria for AD promulgated by the National Institute on Aging-Alzheimer's Association (NIA-AA) in 2011; 4.The patient has good compliance and can cooperate with the collection of clinical data and the evaluation of cognitive function.

Exclusion criteria

Exclusion criteria: 1. Accompanied with serious system complications or complications; 2. Those who have a history of symptomatic stroke, Parkinson's disease, anxiety, depression and other mental disorders and systemic diseases leading to cognitive impairment; 3. Previous diagnosis of central system infectious diseases, epilepsy, intracranial tumors or degenerative diseases of central nervous system; 4. Chronic insomnia, long-term use of sleeping pills, CO or chemical poisoning, and long-term drinking; 5. People with serious visual and hearing impairment and aphasia; 6. Patients with obvious intracranial and extracranial vascular stenosis; 7. Persons with contraindication of magnetic resonance examination and severe claustrophobia.

Design outcomes

Primary

MeasureTime frame
cerebral blood flow;Plasma Aß;neuropsychological testing;Clinical Prediction Model;

Countries

China

Contacts

Public ContactZhu Fangfang

The Second Affiliated Hospital of Bengbu Medical College

490078185@qq.com+86 13721190625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026